- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
EVERSANA Announces Launch of ACTICS
A technology-enabled solution combining predictive analytics integrated with real-time commercial services for the life sciences sector.
EVERSANA today launched ACTICS by EVERSANA, a technology-enabled solution to optimize end-to-end commercial success for life science companies. Combining the power of AI-driven predictive analytics with ready-to-deploy, real-time commercial services, ACTICS provides a cloud-based solution for pharmaceutical innovators to optimize actions in the product and patient journeys.
ACTICS is built on a data-mastering platform and cloud-based infrastructure, enabling the ability to combine multiple data sources into a comprehensive and actionable system. Through API-driven automated intelligence and machine learning technology, ACTICS feeds downstream alerts to additional cloud-based infrastructure, such as a client’s CRM system, to create actionable insights.
ACTICS can also solve specific commercial challenges, such as optimizing market access, evidence creation or patient-finding barriers. Clients can leverage select ACTICS capabilities, including project-based data science services, data accessibility and platform licenses for subscription-based modules and platform applications.
For more information, click here.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
